NP
ASND icon

Ninepoint Partners’s Ascendis Pharma A/S ASND Stock Holding History

Ninepoint Partners’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.93K Sell
26
-5,400
-100% -$1.26M ﹤0.01% 152
2026
Q1 		$1.24M Buy
5,426
+3,311
+157% +$742K 0.09% 85
2025
Q4 		$451K Buy
2,115
+1,366
+182% +$282K 0.05% 121
2025
Q3 		$149K Buy
+749
New +$140K 0.02% 120

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Ninepoint Partners's ASND Position: Q2 2026 in Review

Ninepoint Partners reduced its Ascendis Pharma A/S (ASND) stake by 100% in Q2 2026, selling an estimated $1.26M and leaving 26 shares worth $6.93K. The position accounts for ﹤0.01% of the portfolio, ranked #152.

Ninepoint Partners first reported a position in ASND in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.24M in Q1 2026. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

  • Ninepoint Partners held 26 shares of Ascendis Pharma A/S worth $6.93K as of Q2 2026.
  • Ninepoint Partners sold 5,400 Ascendis Pharma A/S shares in Q2 2026, an estimated $1.26M.
  • Ascendis Pharma A/S made up ﹤0.01% of Ninepoint Partners's portfolio in Q2 2026, its #152 holding.
  • Ninepoint Partners first reported a position in Ascendis Pharma A/S in Q3 2025 and has held it in 4 quarters since.
  • Ninepoint Partners's Ascendis Pharma A/S position peaked at $1.24M in Q1 2026.
  • 312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Ninepoint Partners's 13F filing for Q2 2026, filed 11 Aug 2026.